The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Volumn 20, Issue 17, 2014, Pages 4549-4558

  Backen, Alison ^a   Renehan, Andrew G ^a   Clamp, Andrew R ^a   Berzuini, Carlo ^a   Zhou, Cong ^a   Oza, Amit ^a   Bannoo, Selina ^a   Scherer, Stefan J ^a   Banks, Rosamonde E ^a   Dive, Caroline ^a   Jayson, Gordon C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANGPT1 PROTEIN, HUMAN; BEVACIZUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR EMBOLISM;

ADULT; AGED; ANGIOPOIETIN-1; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964314560     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3248     Document Type: Article

References (0)